IP Library › Granted Patent US 10,015,953
Granted Patent B2
US 10,015,953 · App. 15/000,751 · Granted Jul 10, 2018

Non-human animals having a humanized cluster of differentiation 47 gene

Inventors: Cagan Gurer (Chappaqua, NY); Ella Ioffe (Bronx, NY); Alexander Mujica (Elmsford, NY); Gavin Thurston (Briarcliff Manor, NY)
Assignee: REGENERON PHARMACEUTICALS, INC.
A01K67/0278C07K14/705C07K14/70503C07K14/70596C07K16/2803C12N15/8509G01N33/5011G01N33/5014G01N33/5055G01N33/5088A01K2207/12A01K2207/15A01K2217/052A01K2217/072A01K2217/15A01K2227/105A01K2267/0331A01K2267/0381G01N2333/70596
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,015,953
App. No.
15/000,751
Granted
Jul 10, 2018
Kind
B2
Abstract

Non-human animals, and methods and compositions for making and using the same, are provided, wherein said non-human animals comprise a humanization of an endogenous cluster of differentiation (CD) gene, in particular a humanization of a CD47 gene. Said non-human animals may be described, in some embodiments, as having a genetic modification to an endogenous CD47 gene so that said non-human animals express a CD47 polypeptide that includes a human portion and a non-human portion (e.g., a murine portion).

Claims (17)

1. A genetically modified mouse whose genome comprises a replacement of a genomic fragment comprising exons 2-7 of a mouse CD47 gene at an endogenous mouse CD47 locus with a human genomic fragment comprising exons 2-7 of a human CD47 gene to form a humanized CD47 gene,

wherein the exons of said humanized CD47 gene consist of exon 1 of said mouse CD47 gene, exons 2-7 of said human CD47 gene, and the remaining exons downstream of exon 7 of said mouse CD47 gene,

wherein exons 2-7 of said human CD47 gene encode amino acids 16-292 of SEQ ID NO: 10,

wherein said humanized CD47 gene is under control of the endogenous mouse CD47 promoter at said endogenous mouse CD47 locus, and

wherein said mouse expresses a humanized CD47 protein encoded by said humanized CD47 gene.

2. The genetically modified mouse of claim 1 , whose genome further comprises a replacement of a genomic fragment comprising exons 2, 3 and 4 of a mouse SIRPα gene at an endogenous mouse SIRPα locus with a genomic fragment comprising exons 2, 3 and 4 of a human SIRPα gene to form a humanized SIRPα gene, wherein said humanized SIRPα gene is operably linked to the endogenous mouse SIRPα promoter at said endogenous mouse SIRPα locus, and wherein said humanized SIRPα gene encodes a humanized SIRPα protein comprising an extracellular portion of the human SIRPα protein encoded by said human SIRPα gene and an intracellular portion of the endogenous mouse SIRPα protein encoded by said mouse SIRPα gene.

3. An isolated mouse cell or tissue whose genome comprises a replacement of a genomic fragment comprising exons 2-7 of a mouse CD47 gene at an endogenous mouse CD47 locus with a human genomic fragment comprising exons 2-7 of a human CD47 gene to form a humanized CD47 gene,

wherein the exons of said humanized CD47 gene consist of exon 1 of said mouse CD47 gene, exons 2-7 of said human CD47 gene, and the remaining exons downstream of exon 7 of said mouse CD47 gene,

wherein exons 2-7 of said human CD47 gene encode amino acids 16-292 of SEQ ID NO: 10, and

wherein said humanized CD47 gene is under control of said endogenous mouse CD47 promoter at said endogenous mouse CD47 locus.

4. The isolated mouse cell or tissue of claim 3 , whose genome further comprises a replacement of a genomic fragment comprising exons 2, 3 and 4 of a mouse SIRPα gene at an endogenous mouse SIRPα locus with a genomic fragment comprising exons 2, 3 and 4 of a human SIRPα gene to form a humanized SIRPα gene, wherein said humanized SIRPα gene is operably linked to the endogenous mouse SIRPα promoter at said endogenous mouse SIRPα locus, and wherein said humanized SIRPα gene encodes a humanized SIRPα protein comprising an extracellular portion of the human SIRPα protein encoded by said human SIRPα gene and an intracellular portion of the mouse SIRPα protein encoded by said mouse SIRPα gene.

5. A mouse embryonic stem cell whose genome comprises a replacement of a genomic fragment comprising exons 2-7 of a mouse CD47 gene at an endogenous mouse CD47 locus with a human genomic fragment comprising exons 2-7 of a human CD47 gene to form a humanized CD47 gene,

wherein the exons of said humanized CD47 gene consist of exon 1 of said mouse CD47 gene, exons 2-7 of said human CD47 gene, and the remaining exons downstream of exon 7 of said mouse CD47 gene,

wherein exons 2-7 of said human CD47 gene encode amino acids 16-292 of SEQ ID NO: 10, and

wherein said humanized CD47 gene is under control of the endogenous mouse CD47 promoter at said endogenous mouse CD47 locus.

6. A mouse embryo comprising said mouse embryonic stem cell of claim 5 .

7. The genetically modified mouse of claim 2 , wherein said humanized SIRPα gene comprises exons 1, 5, 6, 7 and 8 of said mouse SIRPα gene.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 4, 2016
From: GURER, CAGAN; IOFFE, ELLA; MUJICA, ALEXANDER; THURSTON, GAVIN
To: REGENERON PHARMACEUTICALS, INC.
Reel/Frame 037666/0839 →
Continuity (3)
Continuation 14951825 · Nov 25, 2015
Provisional Application 62087992 · Dec 5, 2014
Related Publication 20160157470A1 · Jun 9, 2016